Search Within

Dana Elizabeth Rathkopf

  1. "2008"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (1)
Groups
  1. Department of Medicine (5)
  2. Genitourinary Oncology Service (5)
  3. Solid Tumor Oncology Division (5)
  4. Hematologic Malignancies, Division of (3)
  5. Department of Pathology and Laboratory Medicine (2)
  6. GSK Faculty (2)

More Groups

People
  1. Howard Scher (5)
  2. Michael Morris (3)
  3. Susan Slovin (3)
  4. Martin Fleisher (2)
  5. Aseem Anand (1)
  6. Christina Hong (1)

More People

Years
  1. 2008 (5)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Oxford University Press (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Wong, B. Y.; Ross, R. W.; George, D. J.; Picus, J.; Tanaka, E.; Chen, Y.; Atadja, P.; Yang, W.; Culver, K. W.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
    Meeting Abstract

    Danila, D. C.; Rathkopf, D. E.; Morris, M. J.; Slovin, S. F.; Schwartz, L. H.; Farmer, K.; Anand, A.; Haqq, C.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Wong, B. Y.; Ross, R. W.; George, D. J.; Picus, J.; Atadja, P.; Yang, W.; Culver, K. W.; Woo, M. M.; Scher, H. I.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Journal Article

    Rathkopf, D.; Carducci, M. A.; Morris, M. J.; Slovin, S. F.; Eisenberger, M. A.; Pili, R.; Denmeade, S. R.; Kelsen, M.; Curley, T.; Halter, M.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save